Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
Institute of Pathology, University Hospital, LMU Munich, Munich, Germany.
J Cancer Res Clin Oncol. 2023 Jul;149(8):4293-4303. doi: 10.1007/s00432-022-04271-z. Epub 2022 Sep 7.
Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer.
225 specimen of endometrial cancer were immunohistochemically stained for RIG-I and EFTUD2. The results were correlated to clinicopathological data, overall survival (OS) and progression-free survival (PFS).
High RIG-I expression correlated with advanced tumor stages (FIGO: p = 0.027; pT: p = 0.010) and worse survival rates (OS: p = 0.009; PFS: p = 0.022). High EFTUD2 expression correlated to worse survival rates (OS: p = 0.026; PFS: p < 0.001) and was determined to be an independent marker for progression-free survival.
Our data suggest that the expression of RIG-I and EFTUD2 correlates with survival data, which makes both a possible therapeutic target in the future.
子宫内膜癌是最常见的妇科恶性肿瘤。作为先天免疫系统的一部分，解旋酶 RIG-I 和剪接因子 EFTUD2 可以上调 RIG-I 的表达，它们在几种恶性肿瘤中影响肿瘤生长和疾病进展。对于子宫内膜癌这种免疫原性癌症，有关 RIG-I 和 EFTUD2 的数据仍然缺乏。本研究旨在研究 RIG-I 和 EFTUD2 在子宫内膜癌中的表达。
对 225 例子宫内膜癌标本进行 RIG-I 和 EFTUD2 的免疫组织化学染色。将结果与临床病理数据、总生存期 (OS) 和无进展生存期 (PFS) 相关联。
高 RIG-I 表达与晚期肿瘤分期（FIGO：p=0.027；pT：p=0.010）和较差的生存率相关（OS：p=0.009；PFS：p=0.022）。高 EFTUD2 表达与较差的生存率相关（OS：p=0.026；PFS：p<0.001），并被确定为无进展生存期的独立标志物。
我们的数据表明，RIG-I 和 EFTUD2 的表达与生存数据相关，这使得它们成为未来可能的治疗靶点。
